Differential expression of galectin-1 and galectin-3 in canine non-malignant and malignant mammary tissues and in progression to metastases in mammary tumors

Anticancer Research

Volumn 34, Issue 5, 2014, Pages 2211-2222

  De Oliveira, Joana T ^a,b   De Matos, Augusto J ^a   Barros, Rita ^a   Ribeiro, Cláudia ^a   Chen, Asaf ^a   Hespanhol, Venceslau ^c   Rutteman, Gerard R ^d,e   Gartner, Fátima ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSIDADE LUSÓFONA DE HUMANIDADES E TECNOLOGIAS   (Portugal)

^c University of Porto   (Portugal)

^d UTRECHT UNIVERSITY   (Netherlands)

^e Specialist Veterinary Centre De Wagenrenk   (Netherlands)

Author keywords

Canine; Galectin 1; Galectin 3; Mammary tumours; Metastasis; Vessel invasion

Indexed keywords

GALECTIN 1; GALECTIN 3; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BENIGN TUMOR; BREAST TUMOR; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CIRCULATING TUMOR CELL; CONTROLLED STUDY; DISTANT METASTASIS; DOG; FEMALE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NONHUMAN; PATHOLOGY; PROTEIN EXPRESSION; TUMOR GROWTH; UPREGULATION; ANIMAL; BIOSYNTHESIS; CANINE; DISEASE COURSE; DOG DISEASE; EXPERIMENTAL MAMMARY NEOPLASM; GALECTIN-1; GALECTIN-3; IMMUNOHISTOCHEMISTRY; MAMMARY TUMOURS; METABOLISM; VESSEL INVASION;

CANINE; GALECTIN-1; GALECTIN-3; MAMMARY TUMOURS; METASTASIS; VESSEL INVASION;

ANIMALS; DISEASE PROGRESSION; DOG DISEASES; DOGS; FEMALE; GALECTIN 1; GALECTIN 3; IMMUNOHISTOCHEMISTRY; MAMMARY NEOPLASMS, ANIMAL; RNA, MESSENGER;

EID: 84902965988     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Chambers AF, Groom AC and MacDonald IC: Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2(8): 563-572, 2002.
2. Paoloni M and Khanna C: Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 8(2): 147-156, 2008.
3. Sorenmo K: Canine mammary gland tumors. Vet Clin North Am Small Anim Pract 33(3): 573-596, 2003.
4. Liu FT and Rabinovich GA: Galectins as modulators of tumour progression. Nat Rev Cancer 5(1): 29-41, 2005.
5. Honjo Y, Nangia-Makker P, Inohara H and Raz A: Down-regulation of galectin-3 suppresses tumorigenicity of human breast carcinoma cells. Clin Cancer Res 7(3): 661-668, 2001.
6. Scott K and Weinberg C: Galectin-1: a bifunctional regulator of cellular proliferation. Glycoconj J 19(7-9): 467-477, 2004.
7. Nangia-Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, Pienta KJ and Raz A: Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol 156(3): 899-909, 2000.
8. Yoshii T, Fukumori T, Honjo Y, Inohara H, Kim HR and Raz, A: Galectin-3 phosphorylation is required for its anti-Apoptotic function and cell cycle arrest. J Biol Chem 277(9): 6852-6857, 2002.
9. Perillo NL, Pace KE, Seilhamer JJ and Baum LG: Apoptosis of T-cells mediated by galectin-1. Nature 378(6558): 736-739, 1995.
10. Hughes RC: Galectins as modulators of cell adhesion. Biochimie 83(7): 667-676, 2001.
11. Ozeki Y, Matsui T, Yamamoto Y, Funahashi M, Hamako J and Titani, K: Tissue fibronectin is an endogenous ligand for galectin-1. Glycobiology 5(2): 255-261, 1995.
12. van den Brule FA, Buicu C, Berchuck A, Bast RC, Deprez M, Liu FT, Cooper DN, Pieters C, Sobel ME and Castronovo V: Expression of the 67-kDa laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. Hum Pathol 27(11): 1185-1191, 1996.
13. Fischer C, Sanchez-Ruderisch H, Welzel M, Wiedenmann B, Sakai T, André S, Gabius HJ, Khachigian L, Detjen KM and Rosewicz S: Galectin-1 interacts with the {alpha}5{beta}1 fibronectin receptor to restrict carcinoma cell growth via induction of p21 and p27. J Biol Chem 280(44): 37266-37277, 2005.
14. Takenaka Y, Fukumori T and Raz A: Galectin-3 and metastasis. Glycoconj J 19(7-9): 543-549, 2004.
15. Jung EJ, Moon HG, Cho BI, Jeong CY, Joo YT, Lee YJ, Hong SC, Choi SK, Ha WS, Kim JW, Lee CW, Lee JS and Park ST: Galectin-1 expression in cancer-Associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer. Int J Cancer 120(11): 2331-2338, 2007.
16. Kreunin P, Yoo C, Urquidi V, Lubman DM and Goodison S: Proteomic profiling identifies breast tumor metastasis-Associated factors in an isogenic model. Proteomics 7(2): 299-312, 2007.
17. Xu SG, Yan, PJ and Shao ZM: Differential proteomic analysis of a highly metastatic variant of human breast cancer cells using two-dimensional differential gel electrophoresis. J Cancer Res Clin Oncol 136(10): 1545-1556, 2010.
18. Satelli A and Rao US: Galectin-1 is silenced by promoter hypermethylation and its re-expression induces apoptosis in human colorectal cancer cells. Cancer Lett 301(1): 38-46, 2011.
19. Andre S, Sanchez-Ruderisch H, Nakagawa H, Buchholz M, Kopitz J, Forberich P, Kemmner W, Böck C, Deguchi K, Detjen KM, Wiedenmann B, von Knebel Doeberitz M, Gress TM, Nishimura S, Rosewicz S and Gabius HJ: Tumor suppressor p16INK4a-modulator of glycomic profile and galectin-1 expression to increase susceptibility to carbohydrate-dependent induction of anoikis in pancreatic carcinoma cells. FEBS J 274(13): 3233-3256, 2007.
20. Kuramitsu Y, Taba K, Ryozawa S, Yoshida K, Zhang X, Tanaka T, Maehara S, Maehara Y, Sakaida I and Nakamura K: Identification of up-And down-regulated proteins in gemcitabine-resistant pancreatic cancer cells using two-dimensional gel electrophoresis and mass spectrometry. Anticancer Res 30(9): 3367-3372, 2010.
21. Dalotto-Moreno T, Croci DO, Cerliani JP, Martinez-Allo VC, Dergan-Dylon S, Méndez-Huergo SP, Stupirski JC, Mazal D, Osinaga E, Toscano MA, Sundblad V, Rabinovich GA and Salatino, M: Targeting galectin-1 overcomes breast cancer-Associated immunosuppression and prevents metastatic disease. Cancer Res 73(3): 1107-1117, 2013.
22. de Oliveira JT, de Matos AJ, Gomes J, Vilanova M, Hespanhol V, Manninen A, Rutteman G, Chammas R, Gärtner F and Bernardes ES: Coordinated expression of galectin-3 and galectin-3-binding sites in malignant mammary tumors: implications for tumor metastasis. Glycobiology 20(11): 1341-1352, 2010.
23. Castronovo V, Van Den Brûle FA, Jackers P, Clausse N, Liu FT, Gillet C and Sobel ME: Decreased expression of galectin-3 is associated with progression of human breast cancer. J Pathol 179(1): 43-48, 1996.
24. Kim HR, Lin HM, Biliran H and Raz A: Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Res 59(16): 4148-4154, 1999.
25. de Oliveira JT, de Matos AJ, Santos AL, Pinto R, Gomes J, Hespanhol V, Chammas R, Manninen A, Bernardes ES, Albuquerque Reis C, Rutteman G and Gärtner F: Sialylation regulates galectin-3/ligand interplay during mammary tumour progression-A case of targeted uncloaking. Int J Dev Biol 55(7-9): 823-34, 2011.
26. Sanjuan X, Fernández PL, Castells A, Castronovo V, van den Brule F, Liu FT, Cardesa A and Campo E: Differential expression of galectin 3 and galectin 1 in colorectal cancer progression. Gastroenterology 113(6): 1906-1915, 1997.
27. Ellerhorst J, Troncoso P, Xu XC, Lee J and Lotan R: Galectin-1 and galectin-3 expression in human prostate tissue and prostate cancer. Urol Res 27(5): 362-367, 1999.
28. Misdorp W, Else RW, Hellmén E and Lipscomb TP: Histological classification of the mammary tumours of the dog and the cat. In: World Health Organization International Histologic Classification of Tumours of Domestic Animals. Shulman FI (ed.). Armed Forces Institute of Pathology, Washington, DC, USA, pp. 16-29, 1999.
29. Matos AJ, Lopes C, Carvalheira J, Santos M, Rutteman GR and Gärtner FE: Cadherin expression in canine malignant mammary tumours: relationship to other clinicopathological variables. J Comp Pathol 134(2-3): 182-189, 2006.
30. Lana SE, Rutteman GR and Withrow SJ: Tumors of the Mammary Gland. In: Withrow & MacEwen's Small Animal Clinical Oncology, Fourth Edition. Withrow SJ, Vail DM (eds.). W. B. Saunders Company, pp. 619-636, 2007.
31. Paz A, Haklai R, Elad-Sfadia G, Ballan E and Kloog Y: Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene 20(51): 7486-7493, 2001.
32. Kaltner H, Seyrek K, Heck A, Sinowatz F and Gabius HJ: Galectin-1 and galectin-3 in fetal development of bovine respiratory and digestive tracts. Comparison of cell type-specific expression profiles and subcellular localization. Cell Tissue Res 307(1): 35-46, 2002.
33. Vansthertem D, Cludts S, Nonclercq D, Gossiaux A, Saussez S, Legrand A, Gabius HJ and Toubeau G: Immunohistochemical localization of galectins-1 and-3 and monitoring of tissue galectin-binding sites during tubular regeneration after renal ischemia reperfusion in the rat. Histol Histopathol 25(11): 1417-1429, 2010.
34. Yu LG, Andrews N, Zhao Q, McKean D, Williams JF, Connor LJ, Gerasimenko OV, Hilkens J, Hirabayashi J, Kasai K and Rhodes JM: Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-Associated MUC1 causes increased cancer cell endothelial adhesion. J Biol Chem 282(1): 773-781, 2007.
35. Zhao Q, Barclay M, Hilkens J, Guo X, Barrow H, Rhodes JM, and Yu LG: Interaction between circulating galectin-3 and cancer-Associated MUC1 enhances tumour cell homotypic aggregation and prevents anoikis. Mol Cancer 9: 154, 2010.
36. INK4a: Down-regulation of galectin-3, an endogenous competitor of the pro-Anoikis effector galectin-1, in a pancreatic carcinoma model. FEBS J 277(17): 3552-3563, 2010.
37. Shekhar MP, Nangia-Makker P, Tait L, Miller F and Raz A: Alterations in galectin-3 expression and distribution correlate with breast cancer progression: functional analysis of galectin-3 in breast epithelial-endothelial interactions. Am J Pathol 165(6): 1931-1941, 2004.
38. Andre S, Kojima S, Yamazaki N, Fink C, Kaltner H, Kayser K and Gabius HJ: Galectins-1 and-3 and their ligands in tumor biology. Non-uniform properties in cell-surface presentation and modulation of adhesion to matrix glycoproteins for various tumor cell lines, in biodistribution of free and liposome-bound galectins and in their expression by breast and colorectal carcinomas with/without metastatic propensity. J Cancer Res Clin Oncol 125(8-9): 461-474, 1999.
39. Le QT, Shi G, Cao H, Nelson DW, Wang Y, Chen EY, Zhao S, Kong C, Richardson D, O'Byrne KJ, Giaccia AJ and Koong AC: Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol 23(35): 8932-8941, 2005.
40. Greijer AE, van der Groep P, Kemming D, Shvarts A, Semenza GL, Meijer GA, van de Wiel MA, Belien JA, van Diest PJ and van der Wall E: Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). J Pathol 206(3): 291-304, 2005.
41. Gil CD, La M, Perretti M and Oliani SM: Interaction of human neutrophils with endothelial cells regulates the expression of endogenous proteins annexin 1, galectin-1 and galectin-3. Cell Biol Int 30(4): 338-344, 2006.